Skip to content

Amphastar Pharmaceuticals

US · AMPH #3194 by market cap
28.25 +0.14 +0.50%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Maintains Target Price $30
    Market Newswire · 2026/2/25
  • Rating change
    Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Cuts Target Price to $30
    Market Newswire · 2026/2/27
  • Rating change
    Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
    Market Newswire · 2026/7/9
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (CAI), Amphastar Pharmaceuticals (AMPH) and Amylyx Pharmaceuticals Inc (AMLX)
    TipRanks · 2026/5/8
  • Amphastar Pharmaceuticals (AMPH) Gets a Hold From J.P. Morgan
    TipRanks · 2026/10/22
  • Rating change
    Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/4/15
  • Rating change
    Needham Downgrades Amphastar Pharmaceuticals(AMPH.US) to Hold Rating
    Market Newswire · 2026/5/8
  • Rating change
    BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $28
    Market Newswire · 2026/2/27
  • Rating change
    Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20
    Market Newswire · 2026/6/4
  • Rating change
    Wells Fargo Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $20
    Market Newswire · 2026/8/7
  • Rating change
    Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $23
    Market Newswire · 2026/4/8
  • Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $20
    Market Newswire · 2026/8/7
  • Rating change
    Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Cuts Target Price to $30
    Market Newswire · 2026/2/27
  • BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Sell Rating, Raises Target Price to $23
    Market Newswire · 2026/11/7
  • Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $20
    Market Newswire · 2026/8/7
  • Rating change
    Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19
    Market Newswire · 2026/5/14
  • Rating change
    Piper Sandler Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Cuts Target Price to $21
    Market Newswire · 2026/5/11
  • Rating change
    Analysts Offer Insights on Healthcare Companies: CVRx (CVRX), Ardent Health Partners, Inc. (ARDT) and Amphastar Pharmaceuticals (AMPH)
    TipRanks · 2026/6/3
  • Barclays Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Raises Target Price to $23
    Market Newswire · 2026/8/19
  • Rating change
    BofA Securities Downgrades Amphastar Pharmaceuticals(AMPH.US) to Sell Rating, Cuts Target Price to $20
    Market Newswire · 2026/6/29
  • Rating change
    Needham Maintains Amphastar Pharmaceuticals(AMPH.US) With Buy Rating, Maintains Target Price $34
    Market Newswire · 2026/2/25
  • Amphastar Pharmaceuticals (AMPH) Gets a Hold From J.P. Morgan
    TipRanks · 2026/7/23

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:00 · For reference only, not investment advice and not tailored to your situation.

Amphastar Pharmaceuticals discussion 0 comments

Add a comment